Top ten countries for estimated number of adults with diabetes, 1995 and 2025 Country 1995 (millions) Rank 1 India 2 China 3 U.S. 4 Russian Fed. 5 Japan 6 Brazil 7 Indonesia 8 Pakistan 9 Mexico 10 Ukraine All other countries 19.4 16.0 13.9 8.9 6.3 4.9 4.5 4.3 3.8 3.6 49.7 Total 135.3 Country 2025 (millions) India China U.S. Pakistan Indonesia Russian Fed. Mexico Brazil Egypt Japan 57.2 37.6 21.9 14.5 12.4 12.2 11.7 11.6 8.8 8.5 103.6 300.0 GHB DIABETES MELLITUS • Cardio metabolic syndrome • Characterized by persistent Hyperglycaemia due to absolute or relative deficiency of insulin/ insulin resistant. GHB CLASSIFICATION • Primary • Type 1 or insulin dependent diabetes mellitus (IDDM) • Type 2 or non-insulin dependent diabetes mellitus (NIDDM) GHB • Other specific types of diabetes • Pancreatic Disease e.g. Pancreatitis, Haemochromatosis, Neoplastic disease, Pancreatectomy, Cystic Fibrosis GHB • Excess endogenous production of hormonal antagonist to insulin • Growth hormone – Acromagaly • Glucocorticoids – Cushing’s Syndrome • Thyroid hormones – Hyperthyroidism GHB • Catecholamines – Phaeochromocytoma • Human placental lactogen – Pregnancy • Glucagon – Glucagonoma • Counterregulatory hormones – Severe burns, trauma GHB • Medication • e.g. corticosteroids, thiazide diuretics, phenytoin GHB • Associated with genetic syndromes • didmoad-diabetes insipidus, diabetes mellitus, optic atrophy, nerve deafness • lipoatrophy, muscular dystrophies, down’s syndrome, klinefelter’s syndrome, turner’s syndrome GHB ENVIRONMENTAL FACTORS • • • • Bovine serum albumin (cows milk) Viruses Stress Auto immune GHB Gestational Diabetes GHB PATHOPHYSIOLOGY of type 2 diabetes • Complex mechanism • Combination of resistance to action of insulin. • Impaired pancreatic beta cell function. GHB Visceral Fat Topography Visceral Fat GHB INSULIN RESISTANCE • Excessive production of glucose in liver. • Under utilization of glucose in skeletal muscles. • Due to resistance to action of insulin. Hyperinsulinmia Water and Sodium retention Hypertension GHB • Associated, obesity, dyslipidaemia (increased LDL and low HDL) metabolic syndrome • Presence of obesity is amplifier of the insulin resistance GHB Natural History of T2DM Post Meal Glucose 350 250 Glucose Fasting Glucose 150 50 300 Insulin Resistance Relative 200 Function 100 At risk for Diabetes 0 -10 -5 Insulin Level Beta Cell Failure 0 5 10 15 20 25 30 Years of Diabetes GHB Major Factors Involved In Pathogenesis of T2DM Insulin Resistance -Acquisition of visceral obesity…leads to Lipotoxicity, & impaired Insulin signaling Beta Cell Secretory Defects -Impaired first phase insulin release secondary to Lipotoxicity, Glucotoxicity, & loss of Incretion secretion GHB C peptide Proinsulin Ca2+-dependent endopeptidases Insulin MW 5808 PC2 (PC3) A Chain B Chain PC3 GHB Insulin Release: Normal Levels Units: 1 U = 36 µg, i.e. 28 U/mg Daily secretion in humans: 40 - 50 U Basal plasma insulin: 12 µU/ml Postprandial insulin: up to 90 µU/ml 120 Meal 100 80 60 80 40 Basal Minutes 0 20 30 60 90 120 Insulin, U/ml Glucose, mg/dl • • • • GHB Insulin metabolism • Secreted into portal circulation 50% of degradation in liver 50% of degradation in other target tissues and kidney Enzymatic degradation follows receptormediated endocytosis Plasma half-life: 3 - 5 min. – Circulates as free monomer GHB WHAT IS NEW • Intra-abdominal or central adipose tissue is metabolically active. • Release large quantities of FFA. • Compete with glucose as fuel supply for oxidation inhance insulin resistance GHB • Central adipose tissue release number of hormone (adipokines) act on specific receptor influence on insulin sensitivity. • Visceral adipose tissue drain to portal vein influence on liver insulin sensitivity gluconeogenosis and hepetic lipid metabolism. ROLE OF EXERCISE • Inactivity is associated with down regulation of insulin sensitive kinase increased FFA (in muscles) GHB Pancreatic Beta Cell Failure • In early stage Decreased in total mass of pancreatic islet tissue Pancreatic cell damage. What is new • Deposition of amyloid in beta cell beta cell destruction. GHB Hypothesis • Polypeptide (Amylin) is secreted together with insulin. • Form insoluble fibrils of amyloid Destruction of beta cells. • Number of beta cell reduced to 20-30% but alpha cell mass unchanged glucogen secretion increased hyperglycemia. GHB Other Factor GENETIC PREDISPOSITION • Many genes are involved. • More than 200 .. Gene are found. • Three gene polymorphism • Genefor PPARY (Beta cell K ATP channel. • Onchromosoe 1g, 12g – 20g GHB ENVIRONMENTAL FACTOR • Obesity Risk increased when BMI is > 30 kg m2 • Overeating total calorie content (sweat foods and carbohydrate) • Lack of exercise GHB METABOLIC DISTURBANCE • Slow onset of relative insulin deficiency • Lipolysis and glucose uptake is maintained so don’t occur weight loss and keto acidosis. • In type-II diabetes hyperglycemia develops slowly over months or years renal threshold rises osmatic symptoms less marked GHB GHB Clinical Feature • • • • • • • • • Polyuria and thirst Weakness or fatigue Polyphagia and weight loss Blurring of vision Vulvovaginitis or pruritus Nocturnal enuresis Asymptomatic May presented with acute complication May presented with late complications GHB • • Clinical history, physical exam, ambient glucose levels and • degree of ketosis usually suffice appropriate diagnostic • Classification. • In equivocal setting. • a) C-peptide or insulin level (low in type I DM) • b) Glutamic acid decarboxylase a.b • c) Pancreatic islet cell a.b (+ in 90% of new onset type 1 • D.M) • • All action Allow correct classification 31 GHB Clinical Examination • Physical Exam. must include height, weight, blood pressure. • Vision measurement and exam. of eye grounds. • Baseline neurological and cardiovascular exam. should be obtained. • The foot exam. should include peripheral pulses, sensation. • Skin exam. for diabetic dermopathy. GHB • Laboratory Evaluation For Newly Diagnosed Diabetes • • • • • Urinanalysis, Fasting glucose & Random Blood glucose OGTT HbA1C, Fractusamine Test • Other Investitagation • Lipid profile, • , Creatinine, • Electrolytes, TSH. • ECG for patient over 40 years. • should be measured annually. 33 GHB Criteria for Diagnosis Fasting plasma glucose > 126 mg/dl, or Symptoms plus random plasma glucose > 200 mg/dl, or Two-hour plasma glucose > 200 mg/dl on OGTT of 75 gm glucose GHB Criteria for Diagnosis Normal Impaired Diagnostic Fasting < 110 110 – 125 IFG 126 OGTT < 140 140 – 199 IGT 200 GHB Indications For OGTT 1. 2. • • 1. 2. 3. 4. 5. Patients with Impaired Fasting Glycemia (IFG) Pregnant women and postpartum (in women with GDM) * OGTT is performed using a 75 oral glucose load in the morning after a noncaloric 8hr fast. Water is allowed but not coffee or smoking. Types of Curves when performing OGTT Normal curve IGT Diabetic curve Lag storage curve Flat curve 36 GHB Pre-diabetes 1. • 2. • • • • • • • Impaired Fasting Glucose (IFG) FPG 100mg/dl (5.6 mmol/L) to 125 mg/dl (6.9 mmol/L) Impaired Glucose Tolerance (IGT) 2 hr plasma glucose 140mg/dl (7.8 mmol/L) to 199 mg/dl (11.0 mmol/L) Both IFG and IGT are risk factors for future diabetes and for cardiovascular disease and associated with insulin resistance and metabolic syndrome. Unless lifestyle modifications are made most people with prediabetes develop type 2 diabetes within 10 years. 37 GHB HbA1c • Glycosylated haemoglobin • Average blood glucose over last 8-12 weeks • Is not diagnostic GHB GHB MANAGEMENT OF DM • 50% ----DIET • 25% ----OHD • 25%-----INSULIN Type of treatment is determined by serum insulin level or by age and weight (<40 or >40, over wt or normal wt) LIFESTYLE MODIFICATIONS SHOULD BE STRESSED TO ACHIEVE GOAL GHB • Eat less walk more • Reduce calories • Burn calories GHB THERAPEUTIC GOAL NEAR NORMAL METABOLISM 1. 2. 3. Normal blood sugar Normal body weight Normal metabolic profile ALL WILL LEAD TO RETARD VASCULAR AND SPECIFIC DIABETIC COMPLICATIONS GHB DIABETIC DIET 2 TYPES 1. LOW ENERGY, WT-REDUCING DIETS FOR HIGH BMI 2. WT MAINTENANCE DIETS FOR NORMAL BMI GHB AIMS OF DIETRY MANAGEMENT • • • • • • ABOLISHES HYPERGLYCEMIC SYMPTOMS REDUCE BLOOD SUGAR ACHIEVE WT REDUCTION IN OBESE AVOID HYPOGLYCEMIA AVOID WT GAIN AVOID ATHEROGENIC DIET GHB ORAL HYPOGLYCAEMIC DRUGS • MOST DEPENDS UPON SUPPLY OF ENDOGENOUS INSULIN • SUPHONYNUREAS • BIGUNIDES • ALPHA-GLUCOSIDASE INHIBITORS • THIAZOLIDINEDIONES • MEGLITINIDES • INCRETINS • DPP 4 IN HIBITORS • AMYLIN ANALOGUE • SGT INHIBITORS GHB SULPHONYLEUREAS • • • • MECHANISMS INSULIN SECRETOGOGUES DECREASES HEPATIC RELEASE INCREASE IN WT AND PRODUCE INSULIN RESISTANCE • EXAMPLES: 1. FIRST GENERATION---TOLBUTAMIDE AND CHLORPROPAMIDE 2. SECOND GENERATION---GLICLAZIDE , GLIPIZIDE,GLIBENCLAMIDE, GLIMEPRIDE Primary treatment failure and secondary treatment failure GHB BIGUANIDES • MECHANISMS • INCREASE INSULIN SENSITIVITY NAD HENCE INCREASE PERIPHERAL UPTAKE OF GLUCOSE BY TISSUE • IMPAIRS GLUCOSE ABSORPTION FROM GUT • INHIBITS HEPATIC GLUCONEOGENESIS PREFERRED IN OBESE CONTRAINDICATED IN RENAL, HEPATIC FAILURE AND ALCOHOLICS GHB ALPHA-GLUCOSIDASE INHIBITORS • INHIBITS DISACCHARIDASE OF GUT MUCOSA AND HENCE DELAY CHO ABSORPTION • CAUSES FLATULENCE,DIARRHOEA AND ABDOMINAL BLOATING GHB THIAZOLIDINEDIONES(TZD,GLITAZ ONES,PPAR gamma AGONIST) • BINDS AND ACTIVATES PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA , THUS ENHANCING ACTION OF ENDOGENOUS INSULIN—GOOD IN INSULIN RESISTANCE SYNDROM— ROSIGLITAZONE AND PIOGLITAZONE • SHOULD BE COMBINED WITH SU OR METFORMIN • CAUSES FLUID RETENTION (C/I IN CCF) AND OBESITY GHB MEGLITINIDES(ORAL PRANDIAL OR FIRST PHASE INSULIN SECRETOR) • REPAGLINIDE AND NATEGLINIDE GHB DPP4 inhibitors • Sita glipition • Vilda gliption SGT inhibitors • KANA , gliflozin COMBINED ORAL AND INSULIN • IN SECONDARY TREATMENT FAILURE ORAL AND ISOPHANE INSULIN SHOT AT NIGHT CAN BE VERY EFFECTIVE TO PREVENT RESIDUAL BETA CELL FAILURE. • INEFFECTIVE IN C-PEPTIDES NEGATIVE PATIENTS GHB INSULINS(100u/ml) • FAST-ACTING---LISPRO • SHORT-ACTING – SOLUBLE,REGULAR,UNMODIFIED • INTERMEDIATE-ACTING,ISOPHANE ,LANTE,NPH • LONG-ACTING, BOVINE ULTRALENTE • LONG-ACTING,INSULIN ANALOGUE GLARGIN GHB Diabetes Mellitus • Medications • Injectable • Humulin • Glucagon Diabetes Mellitus • Insulin Pumps • Device a little bit larger than a pager that delivers insulin via a small plastic infusion set usually located in abdomen • Infusion set is usually moved every 2-3 days INSULIN THERAPY IN DM TYPE - 2 COMBINATION OF OAA & INSULIN METFORMIN & OR SU AND BEDTIME NPH IF TARGET NOT REACHED IN 4-8 WKS INSULIN STAGE 2 (2/3)R/N(1/2) – 0 –(1/3) R/N (1/1) - 0 INSULIN STAGE 3 (2/3)R/N(1/2) – 0 – R(1/6) – N(1/6) INSULIN STAGE 4 R(20%) – R(25%) – R(25%) – N(30%) How to draw insulin? GHB 1 vial use GHB Humulin-N or Humulin-70/30 GHB GHB 3 Roll the bottle of insulin gently between the palms of your hands .This will mix the insulin well. Do not shake, Shaking leaves air bubbles that can get into the syringe GHB 3 Clean the tip of Bottle with alcohol swab GHB 1 vial use for example 40 units GHB Take the needle cap off the syringe. Hold the syringe with needle pointing toward the ceiling . Keep syringe at eye level , so you can easily see the markings on the barrel. You must put air into the insulin bottle before you can get the insulin out of the bottle .First ,pull the syringe plunger down until the top of the black tip crosses the mark of the dose to be taken .This draws air into the syringe. For example : If you take 40 units of insulin , draw about 40 units of air into syringe . GHB Now turn the syringe tip down . Put the needle through the rubber stopper of the insulin bottle .Push down all the way on the plunger, and hold the plunger in. This puts air into the bottle GHB Make sure the tip of needle is in the insulin .Pull down slowly on the plunger . This brings insulin into the syringe . Pull down slowly on the plunger to the exact line of your insulin dose . The right amount of insulin now be in your syringe Look in the syringe for air bubbles .If you see air bubbles , push the insulin back into the bottle . Then pull the plunger back to the exact line of your insulin dose .If the bubbles are still in the syringe, repeat the process until they are gone. GHB When all the bubbles are out and you have the right dose ,pull the bottle straight up and off the needle .Put the needle cap back on the syringe over the needle . You will know that it’s right if the top of the plunger crosses the right mark on the syringe and there are no air bubbles. Now you are ready to give yourself your shot .Take a deep breath and let it out slowly to help u relax. GHB 2 vials use Mixing 2 vials of Insulin GHB Humulin-R and Humulin-N GHB 1 Gather all of your equipment : Syringe Alcohol swab Insulin 2 Wash your hands. GHB 3 Roll the bottle of insulin gently between the palms of your hands .This will mix the insulin well. Do not shake, Shaking leaves air bubbles that can get into the syringe GHB 3 Clean the tip of Bottle with alcohol swab GHB 2 vials use for example Humulin-N 20 units Humulin-R 10 units GHB Pull 20 units of air into the empty syringe . Put the needle through the rubber stopper of the bottle of cloudy insulin( Humulin N) while its placed on table. Push air into the bottle .Remove the needle. GHB Pull 10 units of air into the same empty syringe .Put the needle into the Humulin Regular (R) insulin bottle . This insulin is clear .Push air into the bottle. GHB With the needle still in the Regular insulin bottle ,turn the bottle upside down . Pull plunger halfway down the syringe . This brings insulin into the syringe .Push the insulin back into the bottle to get rid of the air bubbles . Now pull your dose of insulin into the syringe .Carefully measure 10 units of clear insulin (Humulin R). Pull the syringe out of the bottle GHB Turn the cloudy Humulin N insulin bottle upside down .Put the plunger back slowly to total 30 units .Pull the bottle off the needle. Clear the total dosage . The dose should be : Humulin N (cloudy) 20 units . Humulin R (clear) 10 units . Total of 30 units now in the syringe GHB Sites of Injection GHB Pick a spot from the chart and then find this spot on yourself .Pick a spot at least 1 inch from the place you gave your last shot. If desired .clean the spot with alcohol .Let dry GHB Pick a spot from the chart and then find this spot on yourself .Pick a spot at least 1 inch from the place you gave your last shot. If desired .clean the spot with alcohol .Let dry GHB Pick a spot from the chart and then find this spot on yourself .Pick a spot at least 1 inch from the place you gave your last shot. If desired .clean the spot with alcohol .Let dry GHB Pick a spot from the chart and then find this spot on yourself .Pick a spot at least 1 inch from the place you gave your last shot. If desired .clean the spot with alcohol .Let dry GHB How to inject Humulin? GHB GHB If desired .clean the spot with alcohol .Let dry GHB Remove the top from the needle .Hold the syringe in one hand as you would hold a pencil. With your other hand ,pinch up a couple of inches of skin . GHB Stick the needle straight into the pinched skin .Put the needle all the way in through the skin with one smooth motion Relax the pinch ,and slowly push the plunger all the way down. Be sure the insulin is in ,then remove the needle. GHB Lightly press down on the side BUT don’t RUB. Don’t worry if a drop of blood appears where the needle was. GHB When you are ready to discard your used needles and syringes , break the needle and put them into a hard plastic or metal container with a screw-on lid .Label and discard according to local regulations. GHB TELL YOUR PATIENT TO Record the insulin dose you just gave yourself in your diabetes diary. It may be hard to give yourself a shot for the first time ,but with practice it will become much easier. GHB ACUTE METABOLIC COMPLICATIONS • • • • HYPOGLYCAEMIA DIABETIC KETOACIDOSIS NON-KETOTIC HYPEROSMOLAR COMA LACTIC ACIDOSIS GHB LONG TERM COMPLICATIONS • • • • • • • • DYSLIPIDAEMIA CARDIOVASCULAR DISEASES DIABETIC RETINOPATHY DIABETIC NEPHROPATHY DIABETIC NEUROPATHY DIABETIC FOOT DIABETES AND PREGNANCY DIABETES AND SURGERY GHB Q.1 For diagnosis of diabetes mellitus which of following are true? a) b) c) d) e) Urine for sugar FBS blood sugar more than 126mmd/l HBA1C OGTT RBS More than 200 Q.2 Which of Following are micro vascular complications of diabetes? a) b) c) d) e) Retinopathy Nephropathy Diabetic foot Cataract Neuropathy Q.3, 50 year patient is going for dental surgery his blood sugar is 300 which of following treatment is appropriate? a) b) c) d) e) Metformin Glimepride Rapid acting Insulin Ultra Short Acting Insulin Insulin determir Q.4 Which of the following Drugs are not used in treatment of diabetes with CRF? a) b) c) d) e) Metformin Insulin Captopril Glibenclamide Meglitinide